1. Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota? 
M. Knaapen, R.S. Kootte, E.G. Zoetendal, W.M. de Vos, G.M. Dallinga-Thie, M. Levi, E.S. Stroes, M. Nieuwdorp 
Clinical Microbiology and Infection 
Volume 19, Issue 4, Pages (April 2013)
DOI: /
Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Potential associations between the intestinal microbiota and obesity-related comorbidities, comprising insulin resistance, cardiovascular disease, venous thromboembolic events and non-alcoholic fatty liver disease (NAFLD). GMB, Gut microbiota; LPS, lipopolysaccharide; PAI-1, plasminogen activator inhibitor-1; SCFA, short-chain fatty acid; TMAO, trimethylamine-N-oxide.
Clinical Microbiology and Infection  , DOI: ( / )
Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions